Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

ALL is the most common type of pediatric "...




The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

The most common adverse reactions ( ≥ 10%) in Study 1 were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.

The most common serious adverse reactions in Study 1 were infections (including pneumonia and sepsis), neutropenia, and pyrexia. Infections were the most common adverse reactions leading to drug discontinuation in Study 1.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of monotherapy with ARZERRA was evaluated in 181 patients with relapsed or refractory CLL in 2 open-label, non-randomized, single-arm studies. In these studies, ARZERRA was administered at 2,000 mg beginning with the second dose for 11 doses (Study 1 [n = 154]) or 3 doses (Study 2 [n = 27]).

The data described in Table 2 and other sections below are derived from 154 patients in Study 1. All patients received 2,000 mg weekly from the second dose onward. Ninety percent of patients received at least 8 infusions of ARZERRA and 55% received all 12 infusions. The median age was 63 years (range: 41 to 86 years), 72% were male, and 97% were White.

Table 2: Incidence of All Adverse Reactions Occurring in ≥ 5% of Patients in Study 1 and in the Fludarabine-and Alemtuzumab-Refractory Subset of Study 1 (MedDRA 9.0)

  Total Population
(n =154)
Fludarabine- and Alemtuzumab-Refractory
(n =59)
All Grades Grade ≥ 3 All Grades Grade ≥ 3
Body System/Adverse Event % % % %
Infections and infestations
  Pneumoniaa 23 14 25 15
  Upper respiratory tract infection 11 0 3 0
  Bronchitis 11 < 1 19 2
  Sepsisb 8 8 10 10
  Nasopharyngitis 8 0 8 0
  Herpes zoster 6 1 7 2
  Sinusitis 5 2 3 2
Blood and lymphatic system disorders
  Anemia 16 5 17 8
Psychiatric disorders
  Insomnia 7 0 10 0
Nervous system disorders
  Headache 6 0 7 0
Cardiovascular disorders
  Hypertension 5 0 8 0
  Hypotension 5 0 3 0
  Tachycardia 5 < 1 7 2
Respiratory, thoracic, and mediastinal disorders
  Cough 19 0 19 0
  Dyspnea 14 2 19 5
Gastrointestinal disorders
  Diarrhea 18 0 19 0
  Nausea 11 0 12 0
Skin and subcutaneous tissue disorders
  Rashc 14 < 1 17 2
  Urticaria 8 0 5 0
  Hyperhidrosis 5 0 5 0
Musculoskeletal and connective tissue disorders
  Back pain 8 1 12 2
  Muscle spasms 5 0 3 0
General disorders and administration site conditions
  Pyrexia 20 3 25 5
  Fatigue 15 0 15 0
  Edema peripheral 9 < 1 8 2
  Chills 8 0 10 0
aPneumonia includes pneumonia, lung infection, lobar pneumonia, and bronchopneumonia.
bSepsis includes sepsis, neutropenic sepsis, septic shock.
c Rash includes rash, rash macular, and rash vesicular.

Infusion Reactions

Infusion reactions occurred in 44% of patients on the day of the first infusion (300 mg), 29% on the day of the second infusion (2,000 mg), and less frequently during subsequent infusions.


A total of 108 patients (70%) experienced bacterial, viral, or fungal infections. A total of 45 patients (29%) experienced ≥ Grade 3 infections, of which 19 (12%) were fatal. The proportion of fatal infections in the fludarabine-and alemtuzumab-refractory group was 17%.


Of 108 patients with normal neutrophil counts at baseline, 45 (42%) developed ≥ Grade 3 neutropenia. Nineteen (18%) developed Grade 4 neutropenia. Some patients experienced new onset Grade 4 neutropenia > 2 weeks in duration.


There is a potential for immunogenicity with therapeutic proteins such as ofatumumab. Serum samples from patients with CLL in Study 1 were tested by enzyme-linked immunosorbent assay (ELISA) for anti-ofatumumab antibodies during and after the 24-week treatment period. Results were negative in 46 patients after the 8th infusion and in 33 patients after the 12th infusion.

Immunogenicity assay results are highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to ARZERRA with the incidence of antibodies to other products may be misleading.

Read the Arzerra (ofatumumab injection) Side Effects Center for a complete guide to possible side effects


No formal drug-drug interaction studies have been conducted with ARZERRA.

Read the Arzerra Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 10/17/2013
This monograph has been modified to include the generic and brand name in many instances.


Arzerra - User Reviews

Arzerra User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Arzerra sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.

Health Resources
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations